



Market Announcement

26 May 2022

Race Oncology Ltd (ASX: RAC) – Trading Halt

Description

The securities of Race Oncology Ltd ('RAC') will be placed in trading halt at the request of RAC, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 30 May 2022 or when the announcement is released to the market.

Issued by

Ramona Seeto

Adviser, Listings Compliance (Sydney)

26 May 2022

Ms Alice Montefiore-King
Adviser, Listings Compliance
Australian Securities Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

By email: tradinghaltssydney@asx.com.au

Dear Alice

REQUEST FOR TRADING HALT

Race Oncology Limited (**Company**) (ASX: RAC) requests a trading halt in its securities in accordance with ASX Listing Rule 17.1 effective immediately pending an announcement by the Company in relation to release of clinical results for the dose escalation phase of the 1b/2 Zantrene AML trial in Israel.

The Company requests that the trading halt remain until the earlier of the Company making an announcement with regards to the matter above or the commencement of trading on Monday, 30 May 2022.

The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Authorised for release by Phillip Lynch, CEO/MD on behalf of the Board.

Yours faithfully



Peter Webse
Company Secretary
Race Oncology Ltd